Background: It is uncertain whether kidneys from marginal donors are suitable for live kidney transplantation. In deceased donor kidneys, tubular cell senescence affects allograft function. However, the degree of cell senescence in a living donor kidney with marginal factors has not been reported. In this study, we assessed the association of tubular cell senescence with allograft and remnant kidney function by a prospective observational clinical study. Methods: Thirty-eight living donor kidney transplantations were analyzed prospectively. Tissue sections obtained from preimplantation kidney biopsies were immunostained for p16INK4a to indicate cell senescence. Various kidney biomarkers were analyzed in urine and blood samples. Results: Of the 38 donors, 21 had marginal factors. Severe tubular senescence was found in living donors with overlapping marginal criteria. Tubular senescence in living donor kidneys was significantly related to donor age and lower recipient kidney function at 1 year after transplantation independently of donor age (β = –0.281; p = 0.050) but did not affect remnant kidney function after donation. Pretransplantation donor pre-estimated glomerular filtration rate and hypertension did not show a significant area under the curve (AUC) for prediction of high tubular senescence. High plasma levels of soluble αKlotho were associated with a higher predictive value for low tubular cell senescence with an AUC of 0.78 (95% CI 0.62–0.93; p < 0.01). Conclusions: The nuclear p16-staining rate in donated kidney tubules is a predictor for allograft kidney function but not donor remnant kidney function. Detection of tubular cell senescence may facilitate selection of appropriate living donor candidates.

Keywords:
Tubular cell senescence, p16, Living donor kidney transplantation, Marginal donor, Preimplantation kidney biopsy
1.
Laupacis A, Keown P, Pus N, Krueger H, Ferguson B, Wong C, et al: A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996; 50: 235–242.
2.
Meier-Kriesche HU, Schold JD, Srinivas TR, Reed A, Kaplan B: Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant 2004; 4: 1662–1668.
3.
Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154–2169.
4.
Gómez MP, Pérez B, Manyalich M: International registry in organ donation and transplantation – 2013. Transplant Proc 2014; 46: 1044–1048.
5.
Delmonico F; Council of the Transplantation Society: A report of the Amsterdam Forum on the care of the live kidney donor: data and medical guidelines. Transplantation 2005; 79:S53–S66.
6.
Ferrari P, Lim W, Dent H, McDonald SP: Effect of donor-recipient age difference on graft function and survival in live-donor kidney transplantation. Nephrol Dial Transplant 2011; 26: 702–708.
7.
Sofue T, Inui M, Kiyomoto H, Moritoki M, Nishioka S, Nishijima Y, et al: Pre-existing arteriosclerotic intimal thickening in living-donor kidneys reflects allograft function. Am J Nephrol 2012; 36: 127–135.
8.
Sofue T, Inui M, Hara T, Moriwaki K, Kushida Y, Kakehi Y, et al: Short-term prognosis of living-donor kidney transplantation from hypertensive donors with high-normal albuminuria. Transplantation 2014; 97: 104–110.
9.
Bennett M, Dent CL, Ma Q, Dastrala S, Grenier F, Workman R, et al: Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin J Am Soc Nephrol 2008; 3: 665–673.
10.
Yamashita T, Doi K, Hamasaki Y, Matsubara T, Ishii T, Yahagi N, et al: Evaluation of urinary tissue inhibitor of metalloproteinase-2 in acute kidney injury: a prospective observational study. Crit Care 2014; 18: 716.
11.
Hayflick L, Moorhead PS: The serial cultivation of human diploid cell strains. Exp Cell Res 1961; 25: 585–621.
12.
Ohtani N, Mann DJ, Hara E: Cellular senescence: its role in tumor suppression and aging. Cancer Sci 2009; 100: 792–797.
13.
Melk A: Senescence of renal cells: molecular basis and clinical implications. Nephrol Dial Transplant 2003; 18: 2474–2478.
14.
Susnik N, Melk A, Schmitt R: Cell aging and kidney repair. Cell Cycle 2015; 14: 3521–3522.
15.
Melk A, Schmidt BM, Takeuchi O, Sawitzki B, Rayner DC, Halloran PF: Expression of p16INK4a and other cell cycle regulator and senescence associated genes in aging human kidney. Kidney Int 2004; 65: 510–520.
16.
Braun H, Schmidt BM, Raiss M, Baisantry A, Mircea-Constantin D, Wang S, et al: Cellular senescence limits regenerative capacity and allograft survival. J Am Soc Nephrol 2012; 23: 1467–1473.
17.
Gingell-Littlejohn M, McGuinness D, McGlynn LM, Kingsmore D, Stevenson KS, Koppelstaetter C, et al: Pre-transplant CDKN2A expression in kidney biopsies predicts renal function and is a future component of donor scoring criteria. PLoS One 2013; 8:e68133.
18.
McGlynn LM, Stevenson K, Lamb K, Zino S, Brown M, Prina A, et al: Cellular senescence in pretransplant renal biopsies predicts postoperative organ function. Aging Cell 2009; 8: 45–51.
19.
Melk A, Schmidt BM, Vongwiwatana A, Rayner DC, Halloran PF: Increased expression of senescence-associated cell cycle inhibitor p16INK4a in deteriorating renal transplants and diseased native kidney. Am J Transplant 2005; 5: 1375–1382.
20.
Furuzawa-Carballeda J, Lima G, Alberú J, Palafox D, Uribe-Uribe N, Morales-Buenrostro LE, et al: Infiltrating cellular pattern in kidney graft biopsies translates into forkhead box protein 3 up-regulation and p16INK4α senescence protein down-regulation in patients treated with belatacept compared to cyclosporin A. Clin Exp Immunol 2012; 167: 330–337.
21.
Sis B, Tasanarong A, Khoshjou F, Dadras F, Solez K, Halloran PF: Accelerated expression of senescence associated cell cycle inhibitor p16INK4A in kidneys with glomerular disease. Kidney Int 2007; 71: 218–226.
22.
Westhoff JH, Hilgers KF, Steinbach MP, Hartner A, Klanke B, Amann K, et al: Hypertension induces somatic cellular senescence in rats and humans by induction of cell cycle inhibitor p16INK4a. Hypertension 2008; 52: 123–129.
23.
Verzola D, Gandolfo MT, Gaetani G, Ferraris A, Mangerini R, Ferrario F, et al: Accelerated senescence in the kidneys of patients with type 2 diabetic nephropathy. Am J Physiol Renal Physiol 2008; 295:F1563–F1573.
24.
Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al: Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982–992.
25.
Bennett M, Dent CL, Ma Q, Dastrala S, Grenier F, Workman R, et al: Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin J Am Soc Nephrol 2008; 3: 665–673.
26.
Katsurada A, Hagiwara Y, Miyashita K, Satou R, Miyata K, Ohashi N, et al: Novel sandwich ELISA for human angiotensinogen. Am J Physiol Renal Physiol 2007; 293:F956–F960.
27.
Nagayoshi Y, Kawano H, Hokamaki J, Miyamoto S, Kojima S, Shimomura H, et al: Urinary 8-hydroxy-2’-deoxyguanosine levels increase after reperfusion in acute myocardial infarction and may predict subsequent cardiac events. Am J Cardiol 2005; 95: 514-517.
28.
Seiler S, Rogacev KS, Roth HJ, Shafein P, Emrich I, Neuhaus S, et al: Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2–4. Clin J Am Soc Nephrol 2014; 9: 1049–1058.
29.
Nabeshima Y: Klotho: a fundamental regulator of aging. Ageing Res Rev 2002; 1: 627–638.
30.
Imura A, Iwano A, Tohyama O, Tsuji Y, Nozaki K, Hashimoto N, et al: Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane. FEBS Lett 2004; 565: 143–147.
31.
Kato Y, Arakawa E, Kinoshita S, Shirai A, Furuya A, Yamano K, et al: Establishment of the anti-Klotho monoclonal antibodies and detection of Klotho protein in kidneys. Biochem Biophys Res Commun 2000; 267: 597–602.
32.
Kuro-o M, Nabeshima Y, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, et al: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45–51.
33.
Sato S, Kawamata Y, Takahashi A, Imai Y, Hanyu A, Okuma A, et al: Ablation of the p16(INK4a) tumour suppressor reverses ageing phenotypes of klotho mice. Nat Commun 2015; 6: 7035.
34.
Sugiura H, Yoshida T, Tsuchiya K, Mitobe M, Nishimura S, Shirota S, et al: Klotho reduces apoptosis in experimental ischaemic acute renal failure. Nephrol Dial Transplant 2005; 20: 2636–2645.
35.
Doi S, Zou Y, Togao O, Pastor JV, John GB, Wang L, et al: Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem 2011; 286: 8655–8665.
36.
Hu MC, Kuro-o M, Moe OW: Klotho and chronic kidney disease. Contrib Nephrol 2013; 180: 47–63.
37.
Kitagawa M, Sugiyama H, Morinaga H, Inoue T, Takiue K, Ogawa A, et al: A decreased level of serum soluble Klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease. PLoS One 2013; 8:e56695.
38.
Shimamura Y, Hamada K, Inoue K, Ogata K, Ishihara M, Kagawa T, et al: Serum levels of soluble secreted α-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis. Clin Exp Nephrol 2012; 16: 722–729.
39.
Drew DA, Katz R, Kritchevsky S, Ix J, Shlipak M, Gutiérrez OM, et al: Association between soluble klotho and change in kidney function: the health aging and body composition study. J Am Soc Nephrol 2017; 28: 1859–1866.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.